2월 25일에, Cyagen Biosciences Suzhou Inc.는 2억8500만 위안 (약 4,400 만 달러 상당)의 시리즈 B 파이낸싱을 완성했으며 이 투자는 GF증권(GF securities)가 전액 소유하고 있는 CMS Capital, GF Qianhe, GF Xinde 및 광화투자(Guanghua Investment)가 관리하는 펀드입니다.
Read More ›
Rensselaer, NY — July 18, 2018 - Cyagen Biosciences and Taconic Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership.
Read More ›
Subscribe Now
Keep receiving FREE resources about research trends and promotional offers.
We use cookies to ensure that we give you the best experience on our website. To learn about how we
keep your information safe, view our Privacy Policy.
OKPrivacy policy
